You are here

Our science / Clinical Trials / Find a Trial / NCT00360100

Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media

Back to Search Print Save as PDF Bookmark Trial

NCT00360100

Last updated on May 12, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Bardstown, Kentucky, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Otitis Media
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
3-48 months
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Have clinical signs/symptoms of AOM in at least 1 ear

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Known or suspected hypersensitivity, or intolerance to azithromycin or other
macrolides or to any penicillin, beta-lactam antibiotic or beta lactamase inhibitor

- Previously diagnosed disease(s) of immune function

- Treatment with any systemic (intravenous, intramuscular, oral) antibiotic for any
indication within 7 days prior to enrollment

NCT00360100
Pfizer
Completed
Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Otitis Media, Otitis Media With Effusion, Pneumococcal Infections
Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media
NCT00195611
All Genders
0+
Years
Multiple Sites
Otitis Media
Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media
NCT00360100
All Genders
0+
Years
Multiple Sites
Acute Otitis Media
A Single, High-Dose Azithromycin Extended Release (60 mg/kg) Compared With 10 Days of High-Dose Amoxicillin Clavulanate in Children With Ear Infections at High Risk of Persistent/Recurrent Ear Infections
NCT00643292
All Genders
0+
Years
Multiple Sites
Otitis Media
Study Evaluating Microbiological Analysis of Spontaneous Draining Acute Otitis Media
NCT00768534
All Genders
0+
Years
Tegernsee, Bavarian
Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media
A Randomized, Multicenter, Comparative Study To Assess Tolerability Of A Single Oral 60 Mg/Kg Dose Of Zmax (Pediatric Concentration) Vs. Zmax (Adult Concentration) In Pediatric Patients With Acute Otitis Media
Assess tolerability of different dosing formulations (adult versus pediatric).
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Otitis Media
Drug: Zmax
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
120
December 2006
Not Provided

Inclusion Criteria:

  • Have clinical signs/symptoms of AOM in at least 1 ear

Exclusion Criteria:

  • Known or suspected hypersensitivity, or intolerance to azithromycin or other macrolides or to any penicillin, beta-lactam antibiotic or beta lactamase inhibitor
  • Previously diagnosed disease(s) of immune function
  • Treatment with any systemic (intravenous, intramuscular, oral) antibiotic for any indication within 7 days prior to enrollment
Sexes Eligible for Study: All
3 Months to 48 Months   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Chile,   Costa Rica,   Dominican Republic,   Guatemala,   Panama,   United States
 
 
NCT00360100
A0661170
Not Provided
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
May 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now